Takeda's qdenga®▼ (dengue tetravalent vaccine [live, attenuated]) approved for use in european union

Osaka, japan & cambridge, mass.--( business wire )--takeda ( tse:4502/nyse:tak ) today announced that the european commission (ec) granted marketing authorization for the company's dengue vaccine qdenga® (dengue tetravalent vaccine [live, attenuated]) (tak-003) for the prevention of dengue disease in individuals from four years of age in the european union (eu).i qdenga should be used in accordance with official recommendations. the approval follows the positive recommendation from the european medicines agency's committee for medicinal products for human use (chmp) in october 2022.
TAK Ratings Summary
TAK Quant Ranking